NANOMIX Corp financial data

Industry
Pharmaceutical Preparations
Location
354 Merrimack Street, #4, Lawrence, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
Boston Therapeutics, Inc. (to 11/5/2021), AVANYX Therapeutics, Inc. (to 11/23/2010)
Latest financial report
10-K - Q4 2022 - Apr 7, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.93 % -96.1%
Debt-to-equity -104 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 49M shares +6.05%
Common Stock, Shares, Outstanding 48.8M shares +820%
Entity Public Float 28.8M USD -50.6%
Common Stock, Value, Issued 48.8K USD +820%
Weighted Average Number of Shares Outstanding, Basic 47.7M shares +799%
Weighted Average Number of Shares Outstanding, Diluted 40.5M shares +663%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 15.5K USD
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 3.16M USD +4.71%
General and Administrative Expense 20.4K USD -28.2%
Operating Income (Loss) -8.44M USD -47.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -12.3M USD -30.3%
Net Income (Loss) Attributable to Parent -3.81M USD -54.1%
Earnings Per Share, Basic -0.08 USD/shares +83%
Earnings Per Share, Diluted -0.31 USD/shares +82.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current 4.65K USD
Assets, Current 80.1K USD -82.9%
Property, Plant and Equipment, Net 263K USD -22.5%
Operating Lease, Right-of-Use Asset 570K USD
Other Assets, Noncurrent 617K USD +406%
Assets 982K USD +8.43%
Accounts Payable, Current 903K USD +121%
Accrued Liabilities, Current 730K USD +0.5%
Liabilities, Current 4.05M USD +21.8%
Operating Lease, Liability, Noncurrent 481K USD
Other Liabilities, Noncurrent 556K USD
Liabilities 14.2M USD +104%
Retained Earnings (Accumulated Deficit) -119M USD -11.7%
Stockholders' Equity Attributable to Parent -13.8M USD +36.2%
Liabilities and Equity 982K USD +8.43%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.36M USD -149%
Net Cash Provided by (Used in) Financing Activities 1.1M USD +82.3%
Net Cash Provided by (Used in) Investing Activities -22.6K USD -437%
Common Stock, Shares Authorized 2B shares 0%
Common Stock, Shares, Issued 48.8M shares +820%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -286K USD -657%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 17.1K USD -94.2%
Deferred Tax Assets, Valuation Allowance 21.9M USD +6.93%
Deferred Tax Assets, Gross 21.9M USD +6.93%
Operating Lease, Liability 507K USD
Depreciation 41.7K USD +139%
Payments to Acquire Property, Plant, and Equipment 22.6K USD +437%
Property, Plant and Equipment, Gross 617K USD -22.7%
Operating Lease, Liability, Current 97K USD -67%
Lessee, Operating Lease, Liability, to be Paid, Year Two 177K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 183K USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 188K USD
Additional Paid in Capital 105M USD +23.6%
Interest Expense 505K USD